advertisement
Abstract #8945 Published in IGR 5-2
Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocaprine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients
Kałużny JJ; Szaflik J; Czechowicz-Janicka K; Kałużny J; Orzalkiewicz A; Zaleska A; Krajewska M; Stewart JA; Leech JN; Stewart WCActa Ophthalmologica Scandinavica 2003; 81: 349-
PURPOSE: To establish the efficacy and safety of timolol maleate/dorzolamide fixed combination (TDFC) versus timolol maleate/pilocarpine fixed combination (TPFC), each given twice daily, in primary open-angle glaucoma (POAG) or ocular hypertensive patients. METHODS: In this prospective, multicentered, double-masked trial, 37 patients were treated twice daily with timolol for four weeks. They were then randomized to one of the treatment medications for six weeks, after which they were treated with timolol again for two weeks before being placed on the opposite treatment medication for six weeks. RESULTS: A total of 36 patients completed the trial. Their mean baseline intraocular pressure (IOP) was 22.3 ± 3.7 mmHg. Following six weeks of treatment, the mean trough (08:00 hours) IOP was 18.0 ± 2.2 mmHg for TDFC and 17.4 ± 2.0 mmHg for TPFC (p = 0.22). The mean diurnal curve IOP was 18.1 ± 2.2 mmHg for TDFC and 16.7 ± 1.9 mmHg for TPFC (p = 0.0007). At the remaining time-points (10:00, 18:00, and 20:00 hours), TPFC IOPs were statistically lower than TDFC IOPs (p < 0.03). There was statistically more unsolicited reports of vision change and ocular pain associated with TPFC (p = 0.04). Six patients were discontinued early from TPFC therapy (17%) versus two from TDFC (6%) (p = 0.13). CONCLUSIONS: This study suggests that TPFC can provide at least a similar efficacious reduction in IOP as TDFC in patients with POAG or ocular hypertension.
Dr. J.J. Kałużny, Klinika Okulistyki, Bydgoszcz, Poland
Classification:
11.2 Cholinergic drugs (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
